Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01938716 · ClinicalTrials.gov registry record · NA
Gemcitabine Pharmacokinetics After Preoperative Chemoradiation Therapy
A NA study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- NA
- Development phase
- 12
- Enrollment target
NCT01938716: Clinical Trial NA study, sponsored by M.D. Anderson Cancer Center.
NCT01938716 is a NA study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01938716, a NA study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if gemcitabine given during surgery can enter pancreas cancer cells in patients who have already received chemotherapy and radiation. Gemcitabine is a drug used to treat pancreatic cancer. However, it has not previously been studied if gemcitabine can enter pancreatic cancer cells. Gemcitabine is designed to block the growth of cancer cells, which may cause cancer cells to die.
Interventions
- DRUG Gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2012-03 |
| Est. Completion | 2019-06-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01938716
The ClinicalTrials.gov registry entry for NCT01938716 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gemcitabine is the first listed.
NCT01938716 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01938716 about?
NCT01938716 is a clinical study titled "Gemcitabine Pharmacokinetics After Preoperative Chemoradiation Therapy". The goal of this clinical research study is to learn if gemcitabine given during surgery can enter pancreas cancer cells in patients who have already received chemotherapy and radiation. Gemcitabine is a drug used to treat pancreatic cancer. However, it has not previously been studied if gemcitabin...
What is the current status of trial NCT01938716?
This trial is currently terminated. It is a NA study. The enrollment target is 12 participants. The study started on 2012-03. Estimated completion is 2019-06-03.
What interventions are being tested in trial NCT01938716?
The interventions under investigation include: Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT01938716?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.